ALLERGIES PEANUT Clinical Trials

19 clinical trials for ALLERGIES PEANUT across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE 2, OPEN LABEL STUDY TO ASSESS AD LIB CONSUMPTION OF PEANUT IN PEANUT ALLERGIC INFANTS 6-THROUGH 12-MONTHS-OLD WITH EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 UG (THRIVE) — RECRUITING · PHASE2
• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 ¿G IN 1-THROUGH 3-YEAR OLD CHILDREN WITH PEANUT ALLERGY (COMFORT TODDLERS) — RECRUITING · PHASE3
• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF EPICUTANEOUS IMMUNOTHERAPY WITH DBV712 250 PG IN 4-7- YEAR-OLD CHILDREN WITH PEANUT ALLERGY — RECRUITING · PHASE3
• A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF 6-MONTH OF ABATACEPT VS PLACEBO AS ADJUVANT TO PEANUT ORAL IMMUNOTHERAPY TO INDUCE IMMUNOLOGIC CHANGES IN PATIENTS WITH SEVERE PERSISTENT PEANUT ALLERGY (ATARI) — RECRUITING
• A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PEDIATRIC PATIENTS WITH PEANUT ALLERGY. — RECRUITING
• A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III TRIAL TO ASSESS THE SAFETY AND EFFICACY OF VIASKIN PEANUT IN PEANUT-ALLERGIC YOUNG CHILDREN 1-3 YEARS OF AGE (EPITOPE STUDY) — RECRUITING · PHASE3
• REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSION STUDY (RAMSES OLE) — RECRUITING
• A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY — RECRUITING
• REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN AGES 4 TO 17 YEARS (RAMSES) — RECRUITING
• PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW ON STUDY — RECRUITING
• A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III PIVOTAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF PEANUT EPICUTANEOUS IMMUNOTHERAPY WITH VIASKIN PEANUT IN PEANUT-ALLERGIC CHILDREN — RECRUITING · PHASE3
• "OPEN-LABEL FOLLOW-UP STUDY OF THE VIPES STUDY TO EVALUATE LONG-TERM EFFICACY AND SAFETY OF THE VIASKIN PEANUT." — RECRUITING
• VIASKIN PEANUT PATCH (DBV712) EXPANDED ACCESS CLINICAL TRIAL IN PEANUT-ALLERGIC CHILDREN PREVIOUSLY ENROLLED IN A DBV712 CLINICAL STUDY — NOT_YET_RECRUITING
• A PHASE I OPEN-LABEL TRIAL TO ASSESS THE TOLERABILITY AND SAFETY OF AN UP-DOSING REGIMEN WITH A ONCEDAILY PEANUT SLIT-TABLET IN ADULTS, ADOLESCENTS, AND CHILDREN WITH PEANUT ALLERGY — COMPLETED · PHASE1
• A PROSPECTIVE, RANDOMIZED, CASE CONTROLLED, PILOT STUDY TO EVALUATE THE EFFECT OF RUPATADINE ON THE ADVERSE EVENTS ASSOCIATED WITH PEANUT ORAL IMMUNOTHERAPY ON CHILDREN WITH PEANUT ALLERGIES — NOT_YET_RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND IMMUNOLOGIC EFFECTS OF HAL-MPE1 SUBCUTANEOUS IMMUNOTHERAPY IN ADULT AND PAEDIATRIC SUBJECTS WITH PEANUT ALLERGY — NOT_YET_RECRUITING
• OPEN-LABEL FOLLOW-UP STUDY OF THE PEPITES STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF VIASKIN PEANUT — COMPLETED
• LONG-TERM ASSESSMENT OF SAFETY AND THERAPEUTIC BENEFIT OF VIASKIN PEANUT EPICUTANEOUS TREATMENT IN PEANUT-ALLERGIC CHILDREN. A 6-MONTH RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY FOLLOWED BY AN OPEN LABEL ACTIVE TREATMENT — COMPLETED · PHASE3
• PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (THE PALISADE STUDY) — COMPLETED

Refine this search